Microvesicle-Coated Viral Vectors for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing viral vector-mediated gene delivery technologies face limitations such as off-target gene delivery, toxicity, inefficient delivery to certain cell types, excessive vector uptake by non-target organs, and pre-existing immune responses, particularly in the central nervous system.
Innovation Solution
The use of purified populations of microvesicles associated with viral particles, known as MAVs, which encapsulate or coat viral vectors, shielding them from immune responses and enhancing delivery efficiency by targeting specific cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional viral vectors are used for gene delivery, then delivery capability is achieved, but immune responses and toxicity occur
Solution Approach 1:
The patent uses microvesicles as an intermediary carrier to encapsulate viral vectors. The microvesicle acts as a protective shell that shields the viral vector from immune recognition while maintaining its gene delivery function. This resolves the contradiction by introducing a mediating structure that prevents direct interaction between the immune system and the viral vector.
Solution Approach 2:
The patent employs a nested structure where viral vectors are encapsulated within microvesicles. The viral vector is placed inside the microvesicle compartment, creating a hierarchical delivery system. This nesting approach protects the inner viral vector from external immune factors while preserving its transduction capability.
2Reliability
If viral vectors are used for gene delivery, then transduction is achieved, but off-target delivery and excessive uptake by non-target organs occur
Solution Approach 1:
The patent modifies the microvesicle surface with specific ligands or targeting moieties that provide localized recognition capabilities. This allows the microvesicle-viral vector complex to selectively bind to target cells while avoiding non-target organs, thereby improving targeting precision without compromising transduction efficiency.
3Area of stationary object
If viral vectors are administered systemically, then broad distribution is achieved, but uptake by non-target organs increases
Solution Approach 1:
The patent introduces organ-specific or cell-type-specific targeting ligands on the microvesicle surface that enable selective accumulation in target organs even during systemic circulation. This localized targeting capability allows broad distribution followed by selective uptake in target tissues, resolving the contradiction between distribution range and organ selectivity.
Data Source
AI summary
Disclosed herein are populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.